BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fithian, LLC | 42,979 | $3,562,100 | 16.93% |
Montanaro Asset Management Ltd | 387,800 | $32,140,864 | 5.23% |
Brown Capital Management | 3,301,492 | $273,627,657 | 4.53% |
Ownership Capital B.V. | 2,678,672 | $222,008,335 | 4.36% |
Jackson Square Partners, LLC | 1,927,141 | $159,721,446 | 4.26% |
Sandhill Capital Partners LLC | 468,346 | $38,816,541 | 4.14% |
STONE RUN CAPITAL, LLC | 85,060 | $7,049,773 | 3.56% |
DF DENT & CO INC | 2,639,232 | $218,739,516 | 3.27% |
Spence Asset Management | 224,162 | $18,579 | 3.16% |
Summit Creek Advisors LLC | 261,412 | $21,665,827 | 2.95% |
Pembroke Management, LTD | 323,976 | $26,851,131 | 2.87% |
AMERICAN CAPITAL MANAGEMENT INC | 866,600 | $71,823,808 | 2.81% |
MAIRS & POWER INC | 2,811,030 | $232,978,149 | 2.80% |
Aristotle Atlantic Partners, LLC | 523,203 | $43,363,065 | 2.43% |
Select Equity Group, L.P. | 7,153,947 | $592,919,127 | 2.23% |
GENEVA CAPITAL MANAGEMENT LLC | 1,059,500 | $87,811,360 | 1.97% |
Handelsinvest Investeringsforvaltning | 134,000 | $11,106 | 1.75% |
BAMCO INC /NY/ | 5,519,062 | $457,419,859 | 1.54% |
SANDLER CAPITAL MANAGEMENT | 171,280 | $14,195,686 | 1.46% |
Winslow Capital Management, LLC | 3,147,924 | $260,899,942 | 1.45% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q4 2022. To view BIO-TECHNE CORP's shareholder history, click here.